{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:26:54Z","timestamp":1792610814633,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.diagmicrobio.2013.01.022","type":"journal-article","created":{"date-parts":[[2013,3,18]],"date-time":"2013-03-18T04:16:12Z","timestamp":1363580172000},"page":"402-405","source":"Crossref","is-referenced-by-count":13,"title":["Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria"],"prefix":"10.1016","volume":"75","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin P.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Stilwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/AEM.67.1.22-32.2001","article-title":"Molecular ecology of tetracycline resistance: development and validation of primers for detection of tetracycline resistance genes encoding ribosomal protection proteins","volume":"67","author":"Aminov","year":"2001","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0010","series-title":"The antimicrobic susceptibility test: principles and practices","author":"Barry","year":"1976"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2005.06.004","article-title":"In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)","volume":"52","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0020","series-title":"Antimicrobial agents: antibacterials and antifungals","author":"Bryskier","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-0691.2006.01617.x","article-title":"The contribution of pharmacokinetic-pharmacodynamic modeling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis","volume":"13","author":"Burgess","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0030","series-title":"41st ICAAC, December 16\u201319, 2001. Abst. A-1104. Chicago, IL, USA","article-title":"Magnitude of the 24-h AUC\/MIC required for efficacy of doxycycline against Streptococcus pneumoniae in a murine thigh-infection model","author":"Christianson","year":"2001"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0035","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition, M07-A9","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0040","series-title":"Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0045","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.clinthera.2008.11.006","article-title":"Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007","volume":"30","author":"Dowzicky","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0050","unstructured":"EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. Available at http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed January 2, 2013."},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0055","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1128\/AAC.00939-12","article-title":"Molecular basis for different levels of tet(M) expression in Streptococcus pneumoniae clinical isolates","volume":"56","author":"Grohs","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clinmicnews.2011.08.001","article-title":"Pharmacokinetics-pharmacodynamics: a primer for the clinical microbiologist","volume":"33","author":"Iyer","year":"2011","journal-title":"Clin Microbiol Newsl"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-37923","article-title":"Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997\u20132001)","volume":"24","author":"Jones","year":"2003","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0070","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01046-07","volume":"52","author":"LaPlante","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0075","unstructured":"Minocin\u00ae Product Package Insert, 2010. Triax Pharmaceuticals. Available at http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=32568. Accessed January 2013."},{"key":"10.1016\/j.diagmicrobio.2013.01.022_bb0080","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1128\/AAC.00210-06","article-title":"Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial","volume":"50","author":"Waites","year":"2006","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889313000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T23:55:00Z","timestamp":1539820500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889313000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0732889313000618"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.01.022","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}